Volpara: Edison Open House Healthcare 2022

Volpara Health’s origins go back to our founding CEO Ralph Highnam’s breakthrough research in medical physics and artificial intelligence at the University of Oxford. Volpara has seen tremendous growth by almost every measure.

• Tell us about your breast cancer screening techniques and the particular benefits for clinicians and patients.
• How does your solution help the issue of breast density in the present screening methods?
• What are the current commercial opportunities arising for you?
• How do you choose your partnerships, for example with health authorities rather than equipment manufacturers?
• How might the FDA’s work on breast density legislation affect Volpara?
• How can your technology be used in lung cancer and what competition will you face?
• What other initiatives are you working on that might require future investment and how do these strengthen your overall offering?
• Which milestones should investors focus on in the coming year?